Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 plus adabepilimab vs docetaxel in previously treated non-squamous NSCLC
ChiCTR2600121048Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan and adabepilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecanadabepilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600121048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121048.